Dissemin is shutting down on January 1st, 2025

Published in

eLife Sciences Publications, eLife, (10), 2021

DOI: 10.7554/elife.66537

Links

Tools

Export citation

Search in Google Scholar

Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2

Journal article published in 2021 by Salwa Naushin, Viren Sardana ORCID, Rajat Ujjainiya, Nitin Bhatheja, Rintu Kutum, Akash Kumar Bhaskar, Shalini Pradhan, Satyartha Prakash, Raju Khan, Birendra Singh Rawat, Karthik Bharadwaj Tallapaka, Mahesh Anumalla, Giriraj Ratan Chandak, Amit Lahiri, Susanta Kar and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India) conducted a serosurvey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS-CoV2 anti-nucleocapsid (anti-NC) antibodies, 95% of which had surrogate neutralization activity. Three-fourth of these recalled no symptoms. Repeat serology tests at 3 (n = 607) and 6 (n = 175) months showed stable anti-NC antibodies but declining neutralization activity. Local seropositivity was higher in densely populated cities and was inversely correlated with a 30-day change in regional test positivity rates (TPRs). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of seropositivity were high-exposure work (odds ratio, 95% confidence interval, p value: 2.23, 1.92–2.59, <0.0001), use of public transport (1.79, 1.43–2.24, <0.0001), not smoking (1.52, 1.16–1.99, 0.0257), non-vegetarian diet (1.67, 1.41–1.99, <0.0001), and B blood group (1.36, 1.15–1.61, 0.001).